Your browser doesn't support javascript.
loading
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.
Kramar, A; Negrier, S; Sylvester, R; Joniau, S; Mulders, P; Powles, T; Bex, A; Bonnetain, F; Bossi, A; Bracarda, S; Bukowski, R; Catto, J; Choueiri, T K; Crabb, S; Eisen, T; El Demery, M; Fitzpatrick, J; Flamand, V; Goebell, P J; Gravis, G; Houédé, N; Jacqmin, D; Kaplan, R; Malavaud, B; Massard, C; Melichar, B; Mourey, L; Nathan, P; Pasquier, D; Porta, C; Pouessel, D; Quinn, D; Ravaud, A; Rolland, F; Schmidinger, M; Tombal, B; Tosi, D; Vauleon, E; Volpe, A; Wolter, P; Escudier, B; Filleron, T.
Afiliação
  • Kramar A; Methodology and Biostatistics Unit, Centre Oscar Lambret and SIRIC ONCO LILLE, Lille.
  • Negrier S; Department of Medical Oncology, University of Lyon I, Centre Léon Bérard, Lyon, France.
  • Sylvester R; Department of Biostatistics, EORTC Headquarters, Brussels.
  • Joniau S; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
  • Mulders P; Department of Urology, Radboud University Medical Centre, Nijmegan, The Netherlands.
  • Powles T; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Bex A; Department of Urology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, The Netherlands.
  • Bonnetain F; Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon.
  • Bossi A; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Bracarda S; Department of Oncology, Ospedale San Donato, Arezzo, Italy.
  • Bukowski R; Department of Immunology, Cleveland Clinic Taussig Cancer Center, Cleveland, USA.
  • Catto J; Academic Urology Unit, University of Sheffield, Sheffield, UK.
  • Choueiri TK; Kidney Cancer Center, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Crabb S; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton.
  • Eisen T; Department of Oncology, Cambridge University Health Partners, Cambridge, UK.
  • El Demery M; Department of Medical Oncology, University Hospital of Nîmes, Nimes, France.
  • Fitzpatrick J; Division of Surgery, Mater Misericordiae Hospital and University College Dublin, Dublin, Ireland.
  • Flamand V; Department of Urology, University Lille2 Nord de France, Lille, France.
  • Goebell PJ; Department of Urology, Friedrich-Alexander University Erlangen-Nueremberg, Erlangen, Germany.
  • Gravis G; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille.
  • Houédé N; Department of Medical Oncology, CHU Caremeau, Nîmes.
  • Jacqmin D; Department of Urology, CHRU, Strasbourg, France.
  • Kaplan R; MRC Clinical Trials Unit, University College London, London, UK.
  • Malavaud B; Department of Urology, CHU, Toulouse, France.
  • Massard C; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Melichar B; Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
  • Mourey L; Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse, France.
  • Nathan P; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
  • Pasquier D; Department of Academic Radiation Oncology, Centre Oscar Lambret and SIRIC ONCO LILLE, Lille, France.
  • Porta C; Department of Medical Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Pouessel D; Department of Medical Oncology, Hôpital Saint-Louis, APHP, Paris, France.
  • Quinn D; Division of Oncology, USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, USA.
  • Ravaud A; Department of Medical Oncology, Hôpital Saint André, Bordeaux.
  • Rolland F; Department of Medical Oncology, Institut de cancérologie de l'Ouest-René Gauducheau, Nantes, France.
  • Schmidinger M; Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Tombal B; Department of Urology, Cliniques Universitaires Saint Luc, Brussels, Belgium.
  • Tosi D; Department of Medical Oncology, Institut Régional du Cancer Val d'Aurelle, Montpellier.
  • Vauleon E; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
  • Volpe A; Division of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.
  • Wolter P; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
  • Escudier B; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Filleron T; Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse, France filleron.thomas@iuct-oncopole.fr.
Ann Oncol ; 26(12): 2392-8, 2015 Dec.
Article em En | MEDLINE | ID: mdl-26371288
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Ensaios Clínicos Controlados Aleatórios como Assunto / Fidelidade a Diretrizes / Determinação de Ponto Final / Neoplasias Renais Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Ensaios Clínicos Controlados Aleatórios como Assunto / Fidelidade a Diretrizes / Determinação de Ponto Final / Neoplasias Renais Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article